{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:52:35Z","timestamp":1792101155530,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,2,28]],"date-time":"2017-02-28T00:00:00Z","timestamp":1488240000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Gerontol Geriat"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00391-017-1199-1","type":"journal-article","created":{"date-parts":[[2017,2,28]],"date-time":"2017-02-28T13:30:49Z","timestamp":1488288649000},"page":"703-710","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Crystal arthritides \u2013 gout and calcium pyrophosphate arthritis","Kristall-Arthritiden \u2013 Gicht und Kalziumpyrophosphat-Arthritis"],"prefix":"10.1007","volume":"51","author":[{"given":"S.","family":"Schlee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. C.","family":"Bollheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bertsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. C.","family":"Sieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"H\u00e4rle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,28]]},"reference":[{"key":"1199_CR1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1445-5994.1987.tb01232.x","volume":"17","author":"MJ Ahern","year":"1987","unstructured":"Ahern MJ, Reid C, Gordon TP et\u00a0al (1987) Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 17:301\u2013304","journal-title":"Aust N Z J Med"},{"key":"1199_CR2","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1161\/CIRCULATIONAHA.106.181424","volume":"115","author":"EM Antman","year":"2007","unstructured":"Antman EM, Bennett JS, Daugherty A et\u00a0al (2007) Use of nonsteroidal antiinflammatory drugs: an update for clinicians: A\u00a0scientific statement from the american heart association. Circulation 115:1634\u20131642","journal-title":"Circulation"},{"key":"1199_CR3","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jamda.2013.05.021","volume":"14","author":"J Bauer","year":"2013","unstructured":"Bauer J, Biolo G, Cederholm T et al (2013) Evidence-based recommendations for optimal dietary protein intake in older people: A\u00a0position paper from the PROT-AGE Study Group. J\u00a0Am Med Dir Assoc 14:542\u2013559","journal-title":"J Am Med Dir Assoc"},{"key":"1199_CR4","volume-title":"A phase 3 randomized, controlled, multicenter, double-blind trial comparing effiancy and safety of daily febuxostat and allopurinol in subjects with gout","author":"MSHJ Becker","year":"2008","unstructured":"Becker MSHJ, Espinoza L, Wells A, Macdonald P, Lloyd E, Lademacher C (2008) A phase 3 randomized, controlled, multicenter, double-blind trial comparing effiancy and safety of daily febuxostat and allopurinol in subjects with gout. Meeting of the American College of Rheumatology, San Francisco, California."},{"key":"1199_CR5","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"MA Becker","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR et al (2010) The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 12:R63","journal-title":"Arthritis Res Ther"},{"key":"1199_CR6","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr., Wortmann RL et\u00a0al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N\u00a0Engl J Med 353:2450\u20132461","journal-title":"N Engl J Med"},{"key":"1199_CR7","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/art.20935","volume":"52","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr., Wortmann RL et al (2005) Febuxostat, a\u00a0novel nonpurine selective inhibitor of xanthine oxidase: A\u00a0twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 52:916\u2013923","journal-title":"Arthritis Rheum"},{"key":"1199_CR8","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1001\/archinte.165.7.742","volume":"165","author":"HK Choi","year":"2005","unstructured":"Choi HK, Atkinson K, Karlson EW et al (2005) Obesity, weight change, hypertension, diuretic use, and risk of gout in men: The health professionals follow-up study. Arch Intern Med 165:742\u2013748","journal-title":"Arch Intern Med"},{"key":"1199_CR9","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(04)16000-5","volume":"363","author":"HK Choi","year":"2004","unstructured":"Choi HK, Atkinson K, Karlson EW et\u00a0al (2004) Alcohol intake and risk of incident gout in men: A\u00a0prospective study. Lancet 363:1277\u20131281","journal-title":"Lancet"},{"key":"1199_CR10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/bmj.39449.819271.BE","volume":"336","author":"HK Choi","year":"2008","unstructured":"Choi HK, Curhan G (2008) Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 336:309\u2013312","journal-title":"BMJ"},{"key":"1199_CR11","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1001\/jama.2010.1638","volume":"304","author":"HK Choi","year":"2010","unstructured":"Choi HK, Willett W, Curhan G (2010) Fructose-rich beverages and risk of gout in women. JAMA 304:2270\u20132278","journal-title":"JAMA"},{"key":"1199_CR12","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2217\/bmm.10.94","volume":"4","author":"S Cipriani","year":"2010","unstructured":"Cipriani S, Chen X, Schwarzschild MA (2010) Urate: A\u00a0novel biomarker of Parkinson\u2019s disease risk, diagnosis and prognosis. Biomark Med 4:701\u2013712","journal-title":"Biomark Med"},{"key":"1199_CR13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ageing\/afq140","volume":"40","author":"A Clegg","year":"2011","unstructured":"Clegg A, Young JB (2011) Which medications to avoid in people at risk of delirium: A\u00a0systematic review. Age Ageing 40:23\u201329","journal-title":"Age Ageing"},{"key":"1199_CR14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/ard.59.7.539","volume":"59","author":"PH Dessein","year":"2000","unstructured":"Dessein PH, Shipton EA, Stanwix AE et\u00a0al (2000) Beneficial effects of weight loss associated with moderate calorie\/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: A\u00a0pilot study. Ann Rheum Dis 59:539\u2013543","journal-title":"Ann Rheum Dis"},{"key":"1199_CR15","first-page":"143","volume":"23","author":"TI Evans","year":"1996","unstructured":"Evans TI, Wheeler MT, Small RE et\u00a0al (1996) A comprehensive investigation of inpatient intravenous colchicine use shows more education is needed. J\u00a0Rheumatol 23:143\u2013148","journal-title":"J Rheumatol"},{"key":"1199_CR16","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ana.410320616","volume":"32","author":"S Fahn","year":"1992","unstructured":"Fahn S, Cohen G (1992) The oxidant stress hypothesis in Parkinson\u2019s disease: Evidence supporting it. Ann Neurol 32:804\u2013812","journal-title":"Ann Neurol"},{"key":"1199_CR17","first-page":"2285","volume":"26","author":"C Fernandez","year":"1999","unstructured":"Fernandez C, Noguera R, Gonzalez JA et\u00a0al (1999) Treatment of acute attacks of gout with a\u00a0small dose of intraarticular triamcinolone acetonide. J\u00a0Rheumatol 26:2285\u20132286","journal-title":"J Rheumatol"},{"key":"1199_CR18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"KR Hande","year":"1984","unstructured":"Hande KR, Noone RM, Stone WJ (1984) Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 76:47\u201356","journal-title":"Am J Med"},{"key":"1199_CR19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/ana.10611","volume":"54","author":"MA Hernan","year":"2003","unstructured":"Hernan MA, Chen H, Schwarzschild MA et\u00a0al (2003) Alcohol consumption and the incidence of Parkinson\u2019s disease. Ann Neurol 54:170\u2013175","journal-title":"Ann Neurol"},{"key":"1199_CR20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00002512-200724010-00002","volume":"24","author":"KT Hoskison","year":"2007","unstructured":"Hoskison KT, Wortmann RL (2007) Management of gout in older adults: Barriers to optimal control. Drugs Aging 24:21\u201336","journal-title":"Drugs Aging"},{"key":"1199_CR21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1248\/bpb.b13-00967","volume":"37","author":"K Kaneko","year":"2014","unstructured":"Kaneko K, Aoyagi Y, Fukuuchi T et\u00a0al (2014) Total purine and purine base content of common foodstuffs for facilitating nutritional therapy for gout and hyperuricemia. Biol Pharm Bull 37:709\u2013721","journal-title":"Biol Pharm Bull"},{"key":"1199_CR22","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP et\u00a0al (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 64:1431\u20131446","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1199_CR23","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Khanna PP, Fitzgerald JD et\u00a0al (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 64:1447\u20131461","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1199_CR24","first-page":"39","volume":"4","author":"SR Kingsbury","year":"2011","unstructured":"Kingsbury SR, Conaghan PG, Mcdermott MF (2011) The role of the NLRP3 inflammasome in gout. J\u00a0Inflamm Res 4:39\u201349","journal-title":"J Inflamm Res"},{"key":"1199_CR25","doi-asserted-by":"crossref","first-page":"e005354","DOI":"10.1136\/bmjopen-2014-005354","volume":"4","author":"TM Macdonald","year":"2014","unstructured":"Macdonald TM, Ford I, Nuki G et\u00a0al (2014) Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): A\u00a0large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open 4:e005354","journal-title":"BMJ Open"},{"key":"1199_CR26","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1055\/s-0031-1281570","volume":"136","author":"U Muller-Ladner","year":"2011","unstructured":"Muller-Ladner U, Panzner I, Kriegsmann J et al (2011) Gout \u2013 regardless of therapeutic options a\u00a0\u201cforgotten\u201d disease. Dtsch Med Wochenschr 136:1660\u20131664","journal-title":"Dtsch Med Wochenschr"},{"key":"1199_CR27","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMcp1001124","volume":"364","author":"T Neogi","year":"2011","unstructured":"Neogi T (2011) Clinical practice. Gout. N\u00a0Engl J Med 364:443\u2013452","journal-title":"N Engl J Med"},{"key":"1199_CR28","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/mds.25050","volume":"27","author":"N Palacios","year":"2012","unstructured":"Palacios N, Gao X, O\u2019reilly E et\u00a0al (2012) Alcohol and risk of Parkinson\u2019s disease in a\u00a0large, prospective cohort of men and women. Mov Disord 27:980\u2013987","journal-title":"Mov Disord"},{"key":"1199_CR29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2147\/CIA.S5476","volume":"5","author":"MK Reinders","year":"2010","unstructured":"Reinders MK, Jansen TL (2010) Management of hyperuricemia in gout: focus on febuxostat. Clin Interv Aging 5:7\u201318","journal-title":"Clin Interv Aging"},{"key":"1199_CR30","first-page":"1","volume":"0","author":"P Richette","year":"2016","unstructured":"Richette P, Doherty M, Pascual E et al (2016) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 0:1\u201314","journal-title":"Ann Rheum Dis"},{"key":"1199_CR31","first-page":"331","volume":"29","author":"N Schlesinger","year":"2002","unstructured":"Schlesinger N, Detry MA, Holland BK et\u00a0al (2002) Local ice therapy during bouts of acute gouty arthritis. J\u00a0Rheumatol 29:331\u2013334","journal-title":"J Rheumatol"},{"key":"1199_CR32","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/bmj.324.7352.1488","volume":"324","author":"HR Schumacher Jr.","year":"2002","unstructured":"Schumacher HR Jr., Boice JA, Daikh DI et\u00a0al (2002) Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 324:1488\u20131492","journal-title":"BMJ"},{"key":"1199_CR33","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/annrheumdis-2013-203325","volume":"73","author":"F Sivera","year":"2014","unstructured":"Sivera F, Andres M, Carmona L et al (2014) Multinational evidence-based recommendations for the diagnosis and management of gout: Integrating systematic literature review and expert opinion of a\u00a0broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 73:328\u2013335","journal-title":"Ann Rheum Dis"},{"key":"1199_CR34","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/11592750-000000000-00000","volume":"28","author":"LK Stamp","year":"2011","unstructured":"Stamp LK, Jordan S (2011) The challenges of gout management in the elderly. Drugs Aging 28:591\u2013603","journal-title":"Drugs Aging"},{"key":"1199_CR35","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","volume":"63","author":"LK Stamp","year":"2011","unstructured":"Stamp LK, O\u2019donnell JL, Zhang M et\u00a0al (2011) Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 63:412\u2013421","journal-title":"Arthritis Rheum"},{"key":"1199_CR36","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.amjmed.2007.10.028","volume":"121","author":"AK Tausche","year":"2008","unstructured":"Tausche AK, Aringer M, Schroeder HE et al (2008) The Janus faces of allopurinol-allopurinol hypersensitivity syndrome. Am J Med 121:e3\u2013e4","journal-title":"Am J Med"},{"key":"1199_CR37","first-page":"495","volume":"15","author":"SL Wallace","year":"1988","unstructured":"Wallace SL, Singer JZ (1988) Review: Systemic toxicity associated with the intravenous administration of colchicine \u2013 guidelines for use. J\u00a0Rheumatol 15:495\u2013499","journal-title":"J Rheumatol"},{"key":"1199_CR38","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12916-015-0291-x","volume":"13","author":"ND Yeomans","year":"2015","unstructured":"Yeomans ND (2015) Consensus about managing gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs? BMC Med 13:56","journal-title":"BMC Med"},{"key":"1199_CR39","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/ard.2010.139360","volume":"70","author":"W Zhang","year":"2011","unstructured":"Zhang W, Doherty M, Pascual E et\u00a0al (2011) EULAR recommendations for calcium pyrophosphate deposition. Part\u00a0II: Management. Ann Rheum Dis 70:571\u2013575","journal-title":"Ann Rheum Dis"}],"container-title":["Zeitschrift f\u00fcr Gerontologie und Geriatrie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00391-017-1199-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00391-017-1199-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00391-017-1199-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T12:56:30Z","timestamp":1533041790000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00391-017-1199-1"}},"subtitle":["Part\u00a03: Treatment","Teil\u00a03: Behandlung"],"short-title":[],"issued":{"date-parts":[[2017,2,28]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["1199"],"URL":"https:\/\/doi.org\/10.1007\/s00391-017-1199-1","relation":{},"ISSN":["0948-6704","1435-1269"],"issn-type":[{"value":"0948-6704","type":"print"},{"value":"1435-1269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,28]]}}}